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Greg Russotti to receive the 2019 Award for  
Advancing Manufacture of Cell and Gene Therapy 
 
 
 
 
 
 
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and 
Engineering Conferences International are pleased to announce that Greg Russotti of Celgene is the 
recipient of the 2019 Award for Advancing Manufacture of Cell and Gene Therapy.  The award will be 
presented at the Advancing Manufacture of Cell and Gene Therapy VI conference, January 27-31, 2019 
in Coronado, California. 
 
Greg Russotti has established himself as a world leader in the field of cell therapy technical development 
and manufacturing. He joined Celgene over 12 years ago, just as Celgene began major efforts in the cell 
therapy field.  He was initially responsible for process and analytical development of all cell-based 
processes at Celgene and was soon appointed CMC lead for Celgene’s placental cell therapy product, 
PDA-001, with accountability for all technical operations activities, including process and analytical 
development, clinical production, quality control, quality assurance, and supply chain. Greg later took on 
functional responsibility for the aforementioned areas for all cell and tissue-based products.  
Greg led Celgene’s technical development efforts to drive five different cell therapy products to IND and 
clinical stage, including two different placental cell therapy products, cord blood-derived Natural Killer 
cells, autologous cytotoxic T lymphocytes, and autologous CAR T cells. Greg was awarded Celgene’s 
most prestigious internal award, the John W. Jackson Leadership Award, in 2011 for driving Celgene’s 
decision to build in-house cell therapy manufacturing capabilities and leading Celgene in the cell therapy 
space. This award is given to only one employee in the company each year.  
Greg is known globally as a leader in the field, having given over 25 invited presentations and keynote 
lectures, including two presentations at the FDA, and one at the EMA. He has participated in various 
panel discussions and has given webinars at the largest cell therapy conferences in the US, Canada, and 
Europe. Greg was the meeting co-chair for first four Annual ECI Scale-up and Manufacturing of Cell- 
Based Therapies conferences, from 2012 to 2015, helping shape and build the conference. He remains 
actively involved as a Steering Committee member.  
Greg is actively involved in various national consortia. His roles include: 
- Celgene’s technical cell therapy lead on NIIMBL 
- Executive Committee member of the NSF-funded Center for the Manufacturing of Advanced 
Therapeutics, being led by the Georgia Tech 
- Industrial Executive Board Chairman of the Marcus Center for the Commercialization of Cell 
Therapies ($27MM facility) at Georgia Tech 
- Executive Committee member of NIST-funded American Technology Cell Therapy Manufacturing 
Consortium, led by the Georgia Research Alliance 
- Advisory Board Member of the Cell Therapy Facility at the NJ Institute of Innovation (at NJIT) 
 
Greg has maintained a strong relationship with the academic community by serving in the following roles: 
- Industrial Advisory Board Member in Rutgers University’s Biomedical Engineering and 
Biochemical/Chemical Engineering Departments 
- Guest lecturer in various classes at Rutgers and in past years at Princeton, Columbia, Georgia 
Tech, NC State, NJIT, and Michigan State  
- Lecturer at the International Advanced Course on Regenerative Medicine Manufacturing, hosted 
by Technical University of Lisbon, Loughborough University, and Georgia Tech University, in 
2013 in Portugal and in 2016 in Hilton Head, NC 
 
Greg also designed, organized and taught a graduate level topics-based course, “Bioprocess 
Engineering: Fundamental and Real World Perspectives” in Rutgers University’s Biomedical Engineering 
and Chemical/Biochemical Engineering Departments from 2000 until 2010, after which he passed the 
torch to others who have since led this course, which continues to enjoy success. For his active 
involvement in the Rutgers community and his leadership in the cell therapy field, Greg was awarded the 
Rutgers Engineering School Distinguished Alumnus Medal of Excellence in Education and Research in 
2013. This award is given by Rutgers School of Engineering to one recipient per year. 
Prior to joining Celgene in 2006, Greg spent 15 years at Merck Research Laboratories developing 
products that included live virus vaccines, monoclonal antibodies, recombinant vaccines, and microbially-
produced natural products. He worked on development, scale-up, and tech transfer of cell culture, 
microbial fermentation, and downstream isolation processes to clinical and commercial manufacturing 
facilities. Greg received his B.S. and M.S. degrees in Chemical Engineering from Rensselaer Polytechnic 
Institute and his Ph.D. in Chemical and Biochemical Engineering from Rutgers University.  
Currently, Greg has functional responsibility for all cell therapy development areas at Celgene, including 
cell culture, isolation and formulation process development, analytical development, product attributes 
sciences, development operations, which includes high throughput testing and data automation, clinical 
manufacturing QC, and manufacturing sciences, which supports clinical and commercial manufacturing. 
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Locations and Notes 
 
• Technical sessions will be in the Commodore CDE. Poster Sessions will be in the Bay 
Pavilion. 
• Breakfasts and lunches will be in the Bay Pavilion. 
• Dinner on Sunday and Monday will be in the Bay Pavilion. The conference banquet will be 
in the Commodore Ballroom. 
• The ECI office is in the Boardroom. 
• Audio, still photo and video recording by any device (e.g., cameras, cell phones, laptops, 
PDAs, watches) is strictly prohibited during the technical sessions, unless the author and 
ECI have granted prior permission.Speakers – Please have your presentation loaded 
onto the conference computer prior to the session start (preferably the day before). 
• Speakers – Please leave at least 3-5 minutes for questions and discussion. 
• Please do not smoke at any conference functions. 
• Turn your mobile telephones to vibrate or off during technical sessions. 
• Please write your name on your program so that it can be returned to you if lost or 
misplaced. 
• After the conference, ECI will send an updated participant list to all participants. Please 
check your listing now and if it needs updating, you may correct it at any time by logging 
into your ECI account. 
• Emergency Contact Information: Because of privacy concerns, ECI does not collect or 
maintain emergency contact information for conference participants.  If you would like 
to have this information available in case of emergency, please use the reverse side of 
your name badge. 
 
Follow the conference on Social Media 
Twitter 
twitter.com/ECI_CellGene 
LinkedIn 
www.linkedin.com/showcase/eci-cell-gene-therapies/about/ 
 
 
 
 
 
  
  
Sunday, January 27, 2019 
 
09:00 – 17:00 Pre-conference workshop (Commodore A) 
 Developing a toolkit to engineer viral vector manufacturing and next generation gene therapies 
 
 Workshop Chairs:  Fernanda Masri (Technology Expert for Regenerative Medicine, 
Sartorius Stedim, UK) 
 Michael Greene (Executive Director, Mustang Bio, USA) 
 
16:00 – 19:00 Conference check-in (Atrium) 
 
18:00 – 18:10 Welcome (Commodore C, D, E) 
 ECI Liaison:   Barry Buckland (Chief Executive Officer, BiologicB) 
 
 Conference Chairs: Dolores Baksh (Innovation Leader, GE Healthcare, USA) 
 Rod Rietze (Director, Strategic Development & Innovation, Novartis ) 
Ivan Wall (Professor in Regenerative Medicine, Aston University, UK) 
 
Student Liaison:   Elizabeth Cheeseman (Bioprocess Modeling Research Associate, 
                           Loughborough University, UK)  
 
 
18:10 – 19:30 Plenary 1 – Fireside chat: Delivering commercial cell products 
 
18:10 – 18:15 Introduction 
 Session Chairs:  Dolores Baksh 
                  Rod Rietze 
 
18:15 – 19:30 Plenary 1 
 Timothy Moore (EVP Technical Operations, Kite Pharma – A Gilead Company) 
 Phil Vanek (GM Cell Therapy Strategy, GE Healthcare) 
 Greg Russotti (Vice President, Cell Therapy Technical Development, Celgene) 
Jan Joseph Melenhorst (University of Pennsylvania) 
 
19:30 – 22:00 Welcome reception and dinner (Pavilion) 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Monday, January 28, 2019 (Part 1) 
 
07:00 – 08:30 Breakfast buffet 
 
 Chairs introduction  
 
08:30 – 13:00 Session 1: Advances in cell processing: New technologies for new therapies 
(Session sponsored by FloDesign Sonics) 
 
Session Chairs:  Jeffery Chalmers (Associate Chair and Professor, Chemical & Biomolecular 
Engineering, Ohio State University, USA) 
Thomas Heathman (Business Leader, Manufacturing Development, 
Technology Development & GTP Services, PCT - Hitachi Chemical 
Advanced Therapeutics Solutions, USA) 
08:30 – 08:35 Introduction 
 
08:35 – 09:00 Biomanufacturing cardiac cells from human pluripotent stem cells 
 Sean Palecek (Professor of Chemical & Biological Engineering, University of Wisconsin, USA) 
 
09:00 – 09:20 Acoustic cell processing - An innovation in cell therapy manufacturing 
 Nina Bauer (VP Business Development, FloDesign Sonics, USA) 
 
09:20 – 09:40 Process development and manufacture of primary human T-cells in scalable, 
 automated stirred-tank bioreactors 
 Elena Costariol (PhD Candidate, University College London, UK) 
 
09:40 – 10:00 Animal component free cell culture media development: The approach from the North 
 Panos Chrysanthopoulos (Development Engineer/ Scientist II, CCRM, Canada) 
 
10:00 – 10:30 Transitioning from manual to stirred-tank bioreactor manufacturing of IDCT, An 
 allogeneiccell therapy to treat lumbar degenerative disc disease 
Lara Silverman (Director of Research and Development, DiscGenics, USA) & Gary Pigeau 
(Development Manager - Cell & Gene Therapy, GE Healthcare, USA) 
 
10:30 – 11:00 Morning Break 
 (Sponsored by Cambridge Consultants) 
 
11:00 – 11:30 Scale up of iPSC-derived product manufacturing 
 Peter Fuhrken (Director of Process Engineering, Fujifilm Cellular Dynamics, USA) 
 
11:30 – 11:50 Enabling large-scale ex vivo production of megakaryocytes and platelets from CD34+ cells 
using gas-permeable surfaces and microfluidic bioreactors 
 Andres F. Martinez (PhD Candidate, Northwestern University, USA) 
 
11:50 – 12:10 Functionalized microcarriers for Enhanced CAR T cell manufacturing 
 Nate Dwarshuis (PhD Candidate, Georgia Institute of Technology, USA) 
 
12:10 – 12:40 Scale up of allogeneic cell therapy manufacturing in single-use bioreactors: Challenges, 
insights and solutions 
 Brian Lee (President, PBS Biotech, USA) 
 
12:40 – 13:00 Comparative analysis of FBS containing media and serum free chemically defined 
media, CellCor for adipose derived stem cells production 
 Jooyoun Lee (Head of R&D Center, Xcell Therapeutics, Korea) 
 
13:00 – 14:30 Lunch 
 
  
Monday, January 28, 2019 (Part 2) 
 
14:30 – 15:30 Plenary 2: Gene Therapy 
 
14:30 – 14:35 Introduction to Plenary 2 
 
14:35 – 15:30 Plenary 2 
 Allan Kaspar (Sr VP, Research & Development, AveXis) 
 
15:30 – 17:30 Session 2: Engineering challenges of in vivo gene therapy 
(Session sponsored by GE Healthcare) 
Session Chairs: Fernanda Masri (Technology Expert for Regenerative Medicine, Sartorius Stedim, UK) 
 Michael Greene (Executive Director, Mustang Bio, USA) 
 
15:30 – 15:40  Feedback from ECI Workshop: Developing a toolkit to engineer viral vector manufacturing 
 and next generation gene therapies 
 Fernanda Masri and Michael Greene 
 
15:40 – 16:00 Taking an engineering approach to empower breakthrough therapies 
 Anil Narasimha (Chief Scientific Officer, Mekonos Biotech, USA) 
 
16:00 – 16:20 A single-use chromatographic purification platform for viral gene transfer vectors & 
 viral vaccines 
Pavel Marichal-Gallardo (Bioprocess Engineer, Max Planck Institute for Dynamics of Complex 
Technical Systems, Germany) 
 
16:20 – 16:50 Afternoon Break 
 (Sponsored by CCRM) 
 
16:50 – 17:10 Tangential flow filtration and scalability in viral vector purification 
 Eni Sterjanaj (Downstream Scientist, Pall, USA) 
 
17:10 – 17:30 Scaling up lentiviral vector production from stable producer cells 
 Vanja Misic (Development Scientist, CCRM, Canada) 
 
17:30 – 18:30 Poster Snapshots Session 1 
Session Chairs: Corinne Hoesli (Assistant Professor, Cellular Therapy Bioprocess Engineering 
McGill University, Canada) 
Eric Roos (Strategic Alliances Leader, Cell Therapy, Thermo Fisher Scientific, USA)  
 
18:30 – 22:30 Dinner and poster viewing 
  
Tuesday, January 29, 2019 (Part 1) 
 
07:00 – 08:30 Breakfast buffet 
 
 Chairs introduction 
 
08:30 – 10:35 Session 3: Gene-modification of cells for therapy 
(Session sponsored by PBS Biotech) 
Session Chairs: Peter Jones (Head of Operational Strategy, Oxford BioMedica, UK) 
  Sean Palecek (Professor of Chemical and Biological Engineering, University of 
Wisconsin, Madison, USA) 
 
08:30 – 08:35 Introduction 
 
08:35 – 09:05 Key engineering challenges in the biomanufacturing of lentiviral viral vectors 
 Peter Jones (Head of Technical Operations, Oxford BioMedica, UK) 
 
09:05 – 09:35 Technology transfer of cell and gene therapy products into a new GMP facility: Success 
 factors and key challenges 
 LiYing Yang (Head of MSAT, Lonza) 
 
   09:35 – 09:55 Identification of CAR T Cell Critical Quality Attributes and Critical Process Parameters 
Ryan Larson (Director, Cell Therapy Product Sciences, Juno Therapeutics, USA) 
 
09:55 – 10:15 The development of a 14-day non-viral engineered CAR T-cell process 
 Emi Y. Tokuda (Postdoctoral Fellow, Seattle Children’s Research Institute, USA) 
 
10:15 – 10:35 Effecting clinical starting material quality and the impact to downstream 
processing 
 Dominic Clark (Global Head of Cell Therapy, HemaCare Corporation, USA) 
 
10:35 – 11:05 Morning Break 
 (Sponsored by FUJIFILM Cellular Dynamics, Inc.) 
 
11:05 – 12:05 Plenary 3: Product characterization and analytics 
 
11:05 – 11:10 Introduction to Plenary 3 
 
11:10 – 12:05 Plenary 3 
Jan Joseph Melenhorst (Adjunct Associate Professor of Pathology and Laboratory Medicine, 
University of Pennsylvania, USA) 
 
12:05 – 13:10 Session 4: Product characterization and analytics 
(Session sponsored by Xcell Therapeutics Inc.) 
Session Chairs: Damian Marshall (Director - New and Enabling Technologies Cell and Gene 
Therapy Catapult, UK) 
  Erik Rutjens (Head, New and Enabling Technologies, Cell and Gene Therapy 
Novartis, USA) 
 
12:05 – 12:10 Introduction 
 
12:10 – 12:40 Raman spectroscopy of cells as a process analytical technology 
Jamie Piret (Professor of Chemical & Biological Engineering, University of British Columbia, 
Canada) 
 
 
  
Tuesday, January 29, 2019 (Part 2) 
 
12:40 – 13:10 The dynamic mass spectrometry probe (DMSP) - Advanced process analytics for 
therapeutic cell manufacturing, health monitoring and biomarker discovery  
 Andrei G. Fedorov (Professor of Mechanical Engineering, Georgia Institute of Technology, USA) 
 
13:10 – 14:40 Lunch 
 
14:40 – 15:40 Session 4 (continued): Product characterization and analytics 
 
14:40 – 15:00 Improving functional maturation of human pluripotent stem cells derived cardiomyocytes 
 through metabolic understanding 
 Margarida Serra (Research Associate, IBET/ITQB-UNL, University of Lisbon, Portugal) 
 
15:00 – 15:20 Single cell analysis of viral transduction as a novel toolbox for an improved 
 characterization of cell therapy products 
 Nicole Nicholas (Senior Analytical Development Scientist, Cell & Gene Therapy Catapult, UK) 
 
15:20 – 15:40 Evaluating the impact of culture conditions on human mesenchymal 
 stem/stromal cell-derived exosomes through FTIR spectroscopy 
Ana Fernandes-Platzgummer (Post-Doctoral Research Fellow, Department of Bioengineering 
and iBB, University of Lisbon, Portugal) 
 
15:40 – 16:10 Poster snapshots session 2 
Session Chairs:  Corinne Hoesli (Assistant Professor, Cellular Therapy Bioprocess Engineering 
McGill University, Canada) 
  Eric Roos (Strategic Alliances Leader, Cell Therapy, Thermo Fisher Scientific, 
USA) 
 
16:10 – 18:20 Poster session (with coffee and snacks) 
(Sponsored by the Cell and Gene Therapy Catapult) 
 
18:20 – 18:45 Free time 
 
18:45 – 22:30 Boat cruise, reception, networking, music and dinner 
 
18:45 – 19:15 Boarding reception 
 
19:15 Boat departure 
 
 
 
  
  
Wednesday, January 30, 2019 (Part 1) 
 
07:00 – 09:00 Breakfast buffet 
  
 Chairs introduction 
 
09:00 – 10:00 Plenary 4: Big data processing and analytics 
 
09:00 – 09:05 Introduction to Plenary 4 
 
09:05 – 10:00 Plenary 4 
 James Mault (President and Chief Medical Officer, CQuentia, USA) 
 
10:00 – 11:35 Session 5 - Big data, analytics and control strategies 
Session Chairs: David Pollard (Head of New Materials & Components, Corporate Research, 
Sartorious Stedim, USA) 
  Carolyn Yeago (Georgia Institute of Technology, USA) 
 
10:00 – 10:05 Introduction 
 
10:05 – 10:35 The emerging role for AI in cell and gene therapy manufacture 
 Damian Marshall (Director, New & Enabling Technologies, Cell & Gene Therapy Catapult, UK) 
 
10:35 – 10:55 Efficient model driven design of cell-based product manufacturing 
 Rob Thomas (Professor of Manufacturing for Cell and Gene Therapies, Loughborough University, 
UK) 
 
10:55 – 11:15 Automated data capture and monitoring – An analytics toolbox 
 Dina Ibrahim (Senior Process Engineer, Kite Pharma, USA) 
 
11:15 – 11:35 Using Gaussian mixture models and machine learning to predict donor- dependent 
 megakaryocytic cell growth and differentiation potential ex vivo  
 William Miller (Professor of Chemical & Biological Engineering, Northwestern University, USA) 
 
11:35 – 13:00 Lunch and networking 
 
13:00 – 15:05 Session 6: Bioprocess modeling  
Session Chairs: Suzanne Farid (Professor of Bioprocess Systems Engineering, University College  
London, UK) 
  Jon Gunther (Head of Supply Chain, Sana Biotechnology, USA) 
 
13:00 – 13:05 Introduction 
 
13:05 – 13:30 Establishing successful commercial CAR T manufacturing on a short timeline: A process 
 development and planning perspective 
 Tom Brieva (Senior Director of Process Development, Celgene, USA) 
 
13:30 – 13:55 Novel supply chain and process modeling for cell therapy manufacturing and distribution 
Chip White (Schneider National Chair in Transportation and Logistics, Georgia Institute of 
Technology, USA) 
 
13:55 – 14:20 A roadmap to successful commercialization of autologous CAR T-cell products 
 with centralized and bedside manufacture 
 Tania Pereira Chilima (Post-Doctoral Research Associate, University College London, UK) 
 
 
 
  
Wednesday, January 30, 2019 (Part 2) 
 
14:20 – 14:45 Modeling of commercial autologous cell therapy manufacturing using simulation and 
 optimization 
 David Zhang (Chief Executive Officer, Bio-G, USA) 
 
14:45 – 15:05 Automated data management strategies drive cell therapy success 
 Christophe Suchet (Chief Product Officer, Vineti, USA) 
 
15:05 – 15:30 Afternoon Break 
 (Sponsored by Biolife Solutions and Lonza) 
 
15:30 – 16:35 Session 7: Revolutionizing / delivering the pipelines 
Conference Chairs: Dolores Baksh 
   Rod Rietze 
   Ivan Wall  
 
15:30 – 15:35 Introduction 
 
15:35 – 16:05 The tech enabled pharma company 
 Neil Tiwari (Chief Digital Officer, Novartis, USA) 
 
16:05 – 16:35 Leveraging digital solutions to predict disease and patient access to transformative  
 therapies 
 Ben Newton (Chief Digital Officer, GE Healthcare, USA) 
 
16:35 – 17:30 Advancing manufacture of cell and gene therapies award lecture 
 
16:35 – 16:45 Introduction and presentation of award 
 Barry Buckland (President, ECI Board of Directors) 
 
16:45 – 17:30 Advancing manufacture of cell and gene therapies award lecture 
 Greg Russotti (Vice President, Cell Therapy Technical Development, Celgene, USA) 
 
17:30 – 19:00 Free time and networking 
19:00 – 19:30 Banquet reception and networking 
 
19:30 – 21:30 Conference banquet 
 
 Thalassaemia and gene therapy from a patient’s perspective – Why your work is so  
 important 
 Laurice Levine (β-thalassemia patient and advocate) 
 
Awards and recognition 
 
 
 
Thursday, January 31, 2019 
 
07:00 – 09:00 Breakfast and networking 
 
09:00 – 10:30 Networking 
 
09:00 – 12:00 Hotel check-out 
  
Advancing Manufacture of Cell and Gene Therapies VI 
 
Poster Presentations 
 
 
Advances in cell processing: New technologies for new therapies 
 
1.  BIO regulates the ex vivo expansion and function of hematopoietic stem cells by 
inhibiting GSK-3β 
Qihao Sun (East China University of Science and Technology, China) 
 
2.  Single use disposable BioSettler removes the dead cells and cell debris selectively to 
increase the viability percentage of mammalian cells (e.g., CAR-T) during expansion 
Dhinakar Kompala (Sudhin Biopharma Company, USA) 
 
3.  Use of the Nanobridge system for the Rapid Production of Pluipotent Stem Cells and 
Neural Progenitor Cells 
Peter P. Gray (AIBN, University of Queensland, Australia) 
 
4.  Challenges and opportunities for closed processing in autologous CAR-T manufacturing 
John Wesner (Juno Therapeutics, USA) 
 
5.  Scalable generation of cerebellar neurons from pluripotent stem cells 
Carlos Rodrigues (IST Lisbon, Portugal) 
 
6.  Human pluripotent stem cell expansion in vertical-wheel bioreactors 
Carlos Rodrigues (IST Lisbon, Portugal) 
 
7.  Pancreas organoids for type I diabetes mellitus - Is it feasible as a cell therapy? 
Bart van Dijk (Lonza, Netherlands) 
 
8.  Establishment and evaluation of the suspension culture system for umbilical cord-
derived mesenchymal stromal cells 
Hikari Hasegawa (ROHTO Pharmaceutical Co., Japan) 
 
9.  Scalable manufacturing of human mesenchymal stem/stromal cells and derived 
exosomes in the single-use, vertical-wheel bioreactor system using a human platelet 
lysate culture supplement 
Ana M. Fernandes-Platzgummer (IST Lisbon, Portugal) 
 
10.  Viable manufacture of cell therapies through the integration of multiple unit processes 
onto a counter-flow centrifugation device 
Alexander S. Klarer (Hitachi Chemical Advanced Therapeutic Solutions, USA) 
 
11.  WITHDRAWN 
 
12.  Developing a novel microchannel emulsification device for diabetes cell therapy 
Christina Bitar (McGill University, Canada) 
 
13.  A scalable xeno-free microcarrier suspension bioreactor system for regenerative 
medicine biomanufacturing of hMSCs 
Timothy Olsen (RoosterBio Inc., USA) 
 
 
14.  WITHDRAWN 
 
15.  WITHDRAWN 
 
16.  Further evaluation of a novel COP container system for the cryopreservation of adherent 
and suspension human cell types 
Alexander Lyness (West Pharmaceutical Services, Inc., USA) 
 
17.  Enabling stem cell based therapies: Adaptable and scalable manufacturing of human 
pluripotent stem cells 
Haritha Vallabhaneni (Lonza, USA) 
 
18.  Maintaining CD4/CD8 ratio and Th1-CTL subsets of chimeric antigen receptor (CAR)-T 
cells in serum-free culture conditions 
Hsin-Lin Lu (Development Center for Biotechnology, Taiwan) 
 
19.  Scale-up study for ex-vivo expansion of allogeneic natural killer cells in stirred-tank 
bioreactor 
Juyoung Kim (GreenCross LabCell, South Korea) 
 
20.  A step closer to industrial scale manufacture of exosomes - Adaptation of clinical grade 
neural stem cells from 2D to 3D culture 
Nicola Goddard (University College London, UK) 
 
21.  In vitro high expansion of chimeric antigen receptor (CAR)-T cells in serum-free process 
conditions 
Wei-Kuang Chi (Development Center for Biotechnology, Taiwan) 
 
22.  Reducing variability in conditions for cell handling improves MSC yields 
Ken Rando (BioSpherix, USA) 
 
23.  Impact of the dynamic culture system for 3D high cell density neural differentiation of 
hESC in electrospun PCL scaffolds 
Veronique Chotteau (KTH, Sweden) 
 
24.  Superior expansion of long-term hematopoietic stem cells using StemPro™ HSC medium 
kit 
Chad MacArthur (Thermo Fisher Scientific, USA) 
 
25.  An automated and closed system for patient specific CAR-T cell therapies 
Joseph W. O'Connor (Lonza, USA) 
 
26.  Automated manufacturing for iPSC-derived retinal pigment epithelial cells 
Masahiro Kino-oka (Osaka University, Japan) 
 
27.  Isolation and expansion of human bone marrow-derived mesenchymal stem cells 
(hMSCs) directly on microcarriers in a stirred tank bioreactor 
Christopher J. Hewitt (Aston University, UK) 
 
28.  Mitigating the risks of adventitious agents in serum: Elimination or viral inactivation 
Kelly A. O'Neill (Celgene, USA) 
 
 
 
 
Engineering challenges of in vivo gene therapy 
 
29.  LentiPro stable producer cells: Delivering scalable and reliable lentiviral vector 
manufacturing 
Manuel Carrondo (IBET, Portugal) 
 
30.  Therapeutic genome editing for Charcot-marie-tooth disease type 1a 
Jae young Lee (ToolGen Inc., South Korea) 
 
31.  Engineering characterization of a versatile vertical-wheel bioreactor for cell and gene 
therapy 
Matthew Croughan (Matthew S. Croughan Consulting Services, USA) 
 
32.  A novel scalable manufacturing platform for T-cell activation and expansion in adoptive 
T-cell therapy 
Jian Ling (Southwest Research Institute, USA) 
 
33.  Optimising HEK293T culture for the improved manufacture of gene therapies 
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